Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Invested Capital: 2010-2025

Historic Invested Capital for Myriad Genetics (MYGN) over the last 15 years, with Sep 2025 value amounting to $492.3 million.

  • Myriad Genetics' Invested Capital fell 36.21% to $492.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $492.3 million, marking a year-over-year decrease of 36.21%. This contributed to the annual value of $740.7 million for FY2024, which is 9.86% down from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Invested Capital is $492.3 million, which was up 10.01% from $447.5 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Invested Capital registered a high of $1.0 billion during Q1 2021, and its lowest value of $447.5 million during Q2 2025.
  • Over the past 3 years, Myriad Genetics' median Invested Capital value was $771.7 million (recorded in 2024), while the average stood at $722.9 million.
  • As far as peak fluctuations go, Myriad Genetics' Invested Capital climbed by 6.68% in 2024, and later plummeted by 42.66% in 2025.
  • Quarterly analysis of 5 years shows Myriad Genetics' Invested Capital stood at $967.8 million in 2021, then dropped by 8.47% to $885.8 million in 2022, then fell by 7.24% to $821.7 million in 2023, then declined by 9.86% to $740.7 million in 2024, then tumbled by 36.21% to $492.3 million in 2025.
  • Its Invested Capital was $492.3 million in Q3 2025, compared to $447.5 million in Q2 2025 and $764.2 million in Q1 2025.